The Battle for the Coronary Artery Scan That Saved My Life

My cardiologist had every reason to say no.

I had already been through the full workup. 12-lead ECG. Echocardiogram. Holter monitor. Nuclear stress test. All normal. All clean. A coronary CT angiography, or CCTA, a scan that produces detailed images of the arteries feeding your heart, just eight years earlier had come back pristine. Zero atherosclerosis. Not a speck. I was 44, with no diabetes, no hypertension, no smoking history. My high-sensitivity C-reactive protein, the standard blood marker for systemic inflammation, was 0.45. That is rock bottom. By the usual checklist in front of him, I looked low risk.

To be fair, he was not ignoring obvious heart disease. I had a clean coronary scan only eight years earlier. My mid-back and chest-wall symptoms had another plausible explanation: cervical disc degeneration from decades of heavy lifting, sports, and spinal wear-and-tear, possibly amplified by the hypervigilance that comes with knowing too much. My Holter did show PVCs (premature ventricular contractions, the occasional out-of-sequence beat), but the burden was very low and benign, which could explain a palpitation-type feeling without pointing to dangerous rhythm disease. From his side of the table, there were reasonable non-coronary explanations for what I was feeling.

That is what makes this story matter. The standard explanations were not stupid. They were just incomplete. Something still was not right, and I knew it. My workouts had lost their pep. I was getting tired sooner than normal. Small things that add up but do not show up on an ECG.

I asked for the CCTA again. He hesitated. I kept asking. He agreed.

That scan found the thing every other test missed: an 80% blockage in my right coronary artery.

In the previous post I walked through the standard testing problem: useful tests can still leave the coronary anatomy question unanswered. This post is about what happened next, and about the question I could not stop asking afterward: how did I go from zero disease to an 80% blockage in eight years, with none of the usual explanations?

The fight was not against my cardiologist. It was against the false comfort of being statistically unlikely.

And the harder question underneath it: if the system almost missed someone like me, how many people is it actually missing?

---

The Bottom Line: Rapid coronary artery disease progression without obvious traditional risk factors is uncommon, but it happens. The standard chest-pain workup is largely built to detect ischemia (is the muscle starved for blood right now), while CT coronary angiography looks directly at the anatomy: the plaque and narrowing inside the artery wall. In properly selected symptomatic patients, current guidelines support CCTA early in the diagnostic pathway, but local practice still varies. If your symptoms do not match your "normal" test results, you have the right to ask whether CCTA answers a question the other tests did not. And you should.

---

Vocabulary that matters

• CCTA (CT coronary angiography): a CT scan with contrast dye that images the coronary arteries directly, showing plaque and narrowing.
• Ischemia vs. anatomy: ischemia testing asks whether the heart muscle is starved for blood right now; anatomy testing asks what the artery actually looks like. Different questions.
• hsCRP: a blood test for systemic (whole-body) inflammation. Low is generally good, but it reads your blood, not your artery wall.
• SMuRF-less: shorthand for a patient with none of the Standard Modifiable Risk Factors (no diabetes, hypertension, high cholesterol, or smoking) who has a heart attack anyway.
• CHIP: clonal hematopoiesis of indeterminate potential, an age-related blood-cell mutation increasingly linked to atherosclerosis. More on this below.

---

I'm the Patient the Literature Says Doesn't Exist

Let me be honest about something uncomfortable: the medical literature was mostly on my cardiologist's side.

A 2022 JACC state-of-the-art review on managing cardiovascular risk in young adults focused on the risk factors that predict early-onset disease: family history of premature events, severe hypercholesterolemia, chronic inflammatory conditions, smoking, diabetes.¹ I did not check those boxes. My LDL was mildly elevated, not severe. No family history. No diabetes. Clean prior imaging.

Young adults who have a heart attack with none of the standard modifiable risk factors are uncommon. When researchers queried five years of U.S. hospital admissions in the National Inpatient Sample, of 41,990 STEMI (the most severe, fully-blocked-artery heart attack) patients aged 18 to 45, about 8% were SMuRF-less: 3,495 people with no diabetes, hypertension, high cholesterol, or smoking history.² And here is the unsettling part: those patients had roughly 2.6 times the adjusted odds of dying in the hospital compared with patients who carried the traditional risk factors.² The system is not just slower to find these people. When it does find them, they are sicker than expected.

My cardiologist looked at a 44-year-old with no red flags and a clean CCTA from years earlier. In his position, most clinicians would have made the same call. The guidelines supported it. The statistics supported it. The prior imaging supported it.

The problem is that "statistically unlikely" is cold comfort when you are the outlier.

The Inflammation Problem Nobody Talks About

If you spend any time in the keto, carnivore, or low-carb world, you have heard the argument: mildly elevated LDL cholesterol does not matter as long as your inflammation markers are low and you are "metabolically healthy." The idea is that it is not the cholesterol that does the damage, it is the inflammation. Keep your CRP low and your metabolism clean, and elevated LDL is harmless cargo floating through clean arteries.

I believed this for a long time. My hsCRP was 0.45 mg/L and my continuous glucose data showed excellent metabolic control. By any standard definition, I had no systemic inflammation. And I spent roughly a decade on a ketogenic diet without worrying much about my LDL creeping upward, because the influencers and podcasters I followed told me it was fine.

It was not fine.

Here is what that framework gets wrong, and it is not a small thing: hsCRP measures systemic inflammation, the overall inflammatory state of your blood. What it does not measure is what is happening inside the wall of your arteries.

Researchers at Lund University in Sweden tested this directly. They measured hsCRP in patients undergoing carotid endarterectomy, a surgery where plaque is physically removed from the artery, and compared those blood levels with the actual inflammatory activity inside the extracted plaque tissue. They found no meaningful correlation.³ Your blood marker for inflammation can read clean while the inside of your artery wall is active.

That does not make hsCRP useless. It means a low hsCRP cannot prove the artery wall is quiet. The inflammatory processes that drive atherosclerosis, things like interleukin-6 and other local cytokines, operate at the tissue level, right where the plaque is forming, not at concentrations high enough to reliably show up on a standard blood panel.

The Read A low systemic inflammation marker tells you about your blood, not about the wall of your artery. "My CRP is low, so my LDL is safe" is measuring the wrong thing in the wrong place.

I am not saying keto caused my blockage. I am saying the framework the keto community uses to dismiss LDL risk rests on a measurement that does not measure what they think it does. I broke down the study they rely on most in an earlier post. And I am saying this as someone who followed that framework for years and paid for it.

Commercial distortion risk here is moderate: the "low CRP means safe LDL" message is amplified by a metabolic-health content ecosystem that sells the reassurance. That does not make any single study wrong. It changes how carefully I read the claim.

Why I Might Be an Outlier (And Why You Might Be One Too)

So if it was not the standard risk factors, what was it?

I do not have a definitive answer. Neither do some of the interventional cardiologists at Mayo who have looked at my case and scratched their heads. But there are emerging explanations worth paying attention to, and they are part of why this blog exists. I will go deep on each in its own post. Here they are as breadcrumbs.

Psoriasis. I have it. Mostly in remission for years, a few spots on my knees now and then, minor by any standard. Most people, including many physicians, think of psoriasis as a skin condition. It is not only that. It is a systemic inflammatory disease that shares biological machinery with atherosclerosis. A 2022 study in Nature Communications mapped genetic risk factors shared between psoriasis and coronary artery disease and found evidence of a causal link between the two, tied to systemic inflammation rather than coincidence.⁴ The same molecules that drive psoriatic skin lesions, IL-17 and TNF-alpha, have been shown to drive vascular inflammation and damage the inner lining of arteries in experimental models.⁵ Even when the skin looks calm, that machinery may not be. (More in a future post on the inflammation-biologic connection.)

CHIP. Clonal hematopoiesis of indeterminate potential. One of the most important emerging risk factors in cardiovascular medicine, and almost nobody outside academic cardiology is talking about it. CHIP happens when an acquired mutation in a blood stem cell lets one clone of white blood cells expand and take over a disproportionate share of your blood production. Those cells do not just sit there. A 2024 study in Nature Medicine provided longitudinal human evidence that CHIP can precede and promote new atherosclerosis, and that the relationship appears to run one way: CHIP drives the atherosclerosis, not the reverse.⁶ It is invisible to every standard cardiac workup and blood panel. I have not been tested yet. I am pushing for it, and none of my cardiologists have raised it, which tells you how new this is. (Its own deep dive is coming.)

Or maybe it was not slow at all. Every explanation so far assumes eight years of gradual buildup. But plaque does not only grow slowly. A plaque can rupture or erode, throw a clot that narrows the artery without fully closing it, and then heal over, organizing into a tighter and tighter stenosis. Repeated quiet episodes like that can drive stepwise jumps in blockage that a slow-growth model would never predict.⁷ And not every one of those events announces itself as a crushing-chest-pain heart attack. Unrecognized, silent heart attacks are more common than most people assume; in one cardiac-MRI study of older adults, the silent ones actually outnumbered the recognized ones and still carried real prognostic weight.⁸ I do not know yet whether something like that happened to me. It is one of the threads I am pulling.

Microvascular disease. The arteries you can see on a CCTA are the big pipes. Downstream of them is a network of vessels too small to image, and they can malfunction on their own. Coronary microvascular dysfunction is its own corner of cardiovascular disease, not the same thing as plaque in the large arteries, and it can produce real symptoms and real ischemia while the big vessels look clean.⁹ It matters to my case for two reasons: it is one more way to have normal large-artery tests and still have something genuinely wrong, and the specialized function testing for it is part of how I would try to separate a microvascular cause from the thrombotic story above. It is a test I am actively pushing for.

The point of the breadcrumbs is this: the list of things that can damage a coronary artery, or convincingly mimic that damage, is far longer than a lipid panel and a risk calculator. Some accelerate plaque. Some bypass the slow-growth story entirely. If you carry one that is not on the checklist, the standard system is not built to find you.

The Test That Answers the Anatomy Question

The evidence for CCTA early in the workup for suspected coronary disease is not ambiguous anymore.

The SCOT-HEART trial randomized 4,146 patients to standard care versus standard care plus CCTA. At five years, the CCTA group had a 41% relative reduction in coronary death or nonfatal heart attack: 2.3% versus 3.9%.¹⁰ The 10-year follow-up held: 6.6% versus 8.2% for coronary death or nonfatal myocardial infarction.¹¹ The benefit did not come from more procedures. It came from seeing plaque and acting on it. Think of it this way: telling someone their cholesterol numbers suggest they might develop heart disease someday is like telling them their house might flood. Showing them an actual image of plaque forming in their artery is like showing them water already in the basement. One is a statistic. The other is a reason to act. Doctors started preventive therapy earlier. Patients took it more seriously.

A meta-analysis confirmed the behavioral shift: patients whose imaging showed plaque were nearly three times more likely to start a statin and more than two and a half times more likely to start aspirin.¹² Seeing is believing. It should not have to be, but it is.

The Read The value of the scan is not more stents. It is that no one acts on a risk they cannot see, and seeing the plaque makes it impossible to ignore.

The guideline bodies have moved. The 2021 AHA/ACC chest-pain guideline gives CCTA a Class I recommendation for symptomatic patients without known coronary disease.¹³ The evidence has been there for years; everyday practice is what lags.

PROMISE is the guardrail here. In a large trial of stable, low-to-intermediate-risk chest pain, an anatomy-first CCTA strategy did not beat functional testing on outcomes over short follow-up.¹⁴ So my argument is not "scan everyone." My argument is narrower and, I think, more useful: anatomy and function are two different questions, and a workup that answered everything except the anatomy question is exactly how someone like me gets reassured right up until the scan that changes everything.

One more layer worth knowing about: AI analysis of the scan. A standard CCTA read tells you there is plaque and roughly how much. AI-powered quantitative analysis measures it precisely: the volume, the composition (soft versus calcified), and how it changes over time. In an international multicentre study, deep-learning analysis of CCTA quantified plaque and stenosis and predicted risk in line with expert readers.¹⁵ It is an added cost layer, and insurance coverage is only starting to catch up, but for someone trying to track whether disease is progressing or regressing over years, it can turn a single snapshot into a trend line. That is its own future post.

What I'd Actually Do

If you are having symptoms, even vague ones like exercise intolerance or atypical chest tightness, and your standard workup keeps coming back normal, ask about CCTA. Specifically, and as a question, not a demand.

Try something like this:

"I would like to discuss coronary CT angiography. I understand stress testing looks for ischemia, but CCTA looks at the coronary anatomy directly. Given my persistent symptoms and normal functional testing, I want to understand whether I fit the group where current chest-pain guidelines support CCTA, or why another test is a better first step in my case."

That sentence tells your clinician you have done your homework and frames the visit as a discussion. If they decline, it is reasonable to ask that the request and the reason for declining go into your chart. That is not adversarial. It is good documentation, and clinicians sometimes reconsider when the question and the answer are both on the record.

CCTA is not cheap. It uses IV contrast and can run two thousand dollars or more out of pocket. But weigh that against the alternative: a cascade of stress tests, nuclear imaging, and follow-up visits that may still not answer the anatomy question a single CCTA would. If your insurer requires pre-authorization, ask the office to start it. The 2021 Class I recommendation is the starting point for that conversation.

And if you carry any of the off-checklist risk factors, psoriasis, another autoimmune condition, a family history that does not fit the calculators, or you just know something is off and no one can explain it, keep asking. The system is built for the average patient. If you are not average, you have to be the one who brings the sharper question into the room.

I had every advantage. I am an emergency department nurse at Mayo Clinic. I have a graduate background in bioinformatics. I can cite the guideline and speak the language that makes a cardiologist pause. And it still took all of that to get the test ordered. Most clinicians can follow the logic when the question is framed clearly. Sometimes they just need a patient who knows enough to ask it.

That scan is the reason I am writing this instead of being a statistic. Not everyone has my advantages. But everyone deserves the same information.

The Final Signal

• What the standard tests get right: a normal ECG, echo, Holter, or stress test is real information about rhythm, structure, and blood flow under stress. It is just incomplete.
• What CCTA adds: it answers a different question, what the coronary arteries actually look like, that functional testing can miss.
• The fair read on my cardiologist: he was not irrational for hesitating. The system was working from probability, and I was the outlier. The adversary in this story is probability-based medicine when you do not fit the model, not the person across the desk.
• What does not prove safety: a low hsCRP and good glucose control tell you about your blood and your metabolism. They do not prove the wall of your artery is quiet.
• What is still open: I went from zero plaque to an 80% blockage in eight years with none of the usual explanations. Was it accelerated plaque from an off-checklist driver, a silent thrombotic event that never announced itself, or something the small vessels would explain? I do not know yet. When your symptoms and your workup disagree, the next move is not panic or self-diagnosis. It is a sharper question, and those are the threads I pick up next.

---

Next in the series: I Was Doing Almost Everything Right. It Wasn't Enough. — The biohacker resume, the cracks I did not see, and the question that started a year-long investigation.

---

Would you push for a CCTA if your cardiologist said you did not need one? Have you ever had a "normal" workup that did not match how you felt? I want to hear your story.

References

1. Stone NJ, Smith SC Jr, Orringer CE, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(8):819-836. PMID: 35210038
2. Shamaki GR, Safiriyu I, Antia A, et al. Prevalence, predictors, and in-hospital outcomes of ST-elevation myocardial infarction among young adults without traditional cardiovascular risk factors in the United States. Am Heart J Plus. 2024;43:100408. PMID: 38882592
3. Grufman H, Schiopu A, Edsfeldt A, et al. Plasma levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques. J Intern Med. 2014;275(2):127-133. PMID: 24010553
4. Patrick MT, Stuart PE, Zhang H, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1):6565. PMID: 36323703
5. Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658-2668. PMID: 25341795
6. Díez-Díez M, Ramos-Neble BL, de la Barrera J, et al. Unidirectional association of clonal hematopoiesis with atherosclerosis development. Nat Med. 2024;30(10):2857-2866. PMID: 39215150
7. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999;82(3):265-268. PMID: 10455072
8. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308(9):890-896. PMID: 22948699
9. Del Buono MG, Montone RA, Camilli M, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352-1371. PMID: 34556322
10. SCOT-HEART Investigators, Newby DE, Adamson PD, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379(10):924-933. PMID: 30145934
11. Williams MC, Wereski R, Tuck C, et al.; SCOT-HEART Investigators. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. Lancet. 2025;405(10475):329-337. PMID: 39863372
12. Gupta A, Lau E, Varshney R, et al. The Identification of Calcified Coronary Plaque Is Associated With Initiation and Continuation of Pharmacological and Lifestyle Preventive Therapies: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. 2017;10(8):833-842. PMID: 28797402
13. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021;144(22):e368-e454. PMID: 34709879
14. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease (PROMISE). N Engl J Med. 2015;372(14):1291-1300. PMID: 25773919
15. Lin A, Manral N, McElhinney P, et al. Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study. Lancet Digit Health. 2022;4(4):e256-e265. PMID: 35337643